

## **LONGITUDE CAPITAL MAINTAINS MOMENTUM WITH PROMOTIONS AND TEAM EXPANSION**

**Menlo Park, CA and Greenwich, CT, March 17, 2014** – Longitude Capital, a private investment firm that focuses on venture growth investments in drug development and medical technology, today announced the promotions of Josh Richardson, M.D., to Principal and Mark Chin to Vice President, as well as the additions of Sandip Agarwala as a Principal and Andrew ElBardissi, M.D., as a Vice President.

Dr. Richardson joined Longitude in 2011 and focuses on investments in biotechnology. He has been involved with the firm's investments in Allergen Research Corporation, Cadence Pharmaceuticals (NASDAQ: CADX), Collegium Pharmaceutical, Precision Dermatology and Rapid Micro Biosystems. Prior to joining Longitude, Dr. Richardson was an Engagement Manager with McKinsey & Company, where he worked in the Pharmaceutical and Private Equity practices. He holds an M.D. from the University of Virginia and a B.S. *magna cum laude* in biomedical science from the University of South Florida.

Mr. Chin joined Longitude in 2012 and focuses on investments across medical technology. He has been involved with the firm's investments in Ajax Medical and Sympara Medical. Prior to joining Longitude Capital, he was a Consultant at the Boston Consulting Group, and previously worked in corporate development at Gilead Sciences and Market Planning at Genentech. Mr. Chin holds an M.B.A. from the Wharton School of Business at the University of Pennsylvania, an M.S. in Biotechnology from the University of Pennsylvania, and a B.S. in Management Science from the University of California at San Diego.

"Josh has been an important resource for our portfolio companies and our own internal processes, and we are excited to recognize his accomplishments through this promotion," said Patrick Enright, a Managing Director at Longitude. "Mark has helped us scale our efforts efficiently and has been a strong contributor to both the biotechnology and medical technology sector teams at Longitude."

"In addition to these promotions, we are delighted to add two highly qualified individuals to our investment team," said Juliet Tammenoms Bakker, a Managing Director of Longitude. "Both Sandip and Andrew are already making significant contributions to Longitude."

Mr. Agarwala is focused on structured investments in both biotechnology and medical device companies. Prior to joining Longitude, Mr. Agarwala was a Vice President with Auvén Therapeutics (formerly Celtic Therapeutics), a private equity firm that invests in late-development stage biopharmaceutical projects and companies. Before joining Auvén, he was a Consultant in the healthcare practice at the Boston Consulting Group. Mr. Agarwala's professional experience also includes roles with Healthcare Royalty Partners, Paul Capital Partners, and The Frankel Group, a boutique healthcare consulting firm. He holds an M.B.A. in Finance and Health Care Management from the Wharton School of Business at the University of Pennsylvania, and a B.S.E. in Systems Engineering from the University of Pennsylvania.

Dr. ElBardissi focuses on investments in medical technology. Prior to joining Longitude Capital, he was an Associate in J.P. Morgan's Healthcare Investment Banking practice, where he served clients in biotechnology, medical technology, and healthcare services. He holds an M.D. from the Mayo Clinic, an M.P.H. in Quantitative Methods from Harvard University, an M.B.A. from Harvard Business School, and a B.S. with honors in Biology (Phi Beta Kappa) from the Schreyer Honors College at the Pennsylvania State University. Dr. ElBardissi received residency training in General Surgery at Harvard Medical School's Brigham and Women's Hospital and in Cardiothoracic Surgery at Stanford University.

### **About Longitude Capital**

Longitude Capital ([www.longitudecapital.com](http://www.longitudecapital.com)) is a private investment firm that focuses on venture growth investments in drug development and medical technology. The firm builds balanced portfolios of mid-stage to commercial-stage companies with clinically de-risked assets that are likely to achieve key value-creating milestones within three to five years. Besides traditional venture capital investments, Longitude's investment team also proactively searches for "special situations", such as spin-outs, recapitalizations, PIPEs and structured transactions, across both privately-held and publicly-traded companies.

Founded in 2006, Longitude Capital consists of twelve investment professionals and operates bi-coastally with offices in Menlo Park, CA and Greenwich, CT. Prior investments made by the team at both Longitude and their predecessor firm include Ablation Frontiers, Aptus Endosystems, Cadence Pharmaceuticals (CADX), Civitas Therapeutics, Insulet Corporation (PODD), Jazz Pharmaceuticals (JAZZ), MAP Pharmaceuticals (MAPP), NxStage Medical (NXTM), Precision Dermatology, Sadra Medical, Sequenom (SQNM), and Threshold Pharmaceuticals (THLD). Longitude Capital has over \$700 million in assets under management, and most recently raised \$385 million for its second fund, Longitude Venture Partners II, L.P., in 2012.